Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients by unknown
RESEARCH ARTICLE Open Access
Proportion and factors associated with
Hepatitis B viremia in antiretroviral
treatment naïve and experienced HIV
co-infected Ghanaian patients
Timothy N. A. Archampong1,2*, Margaret Lartey1,2, Kwamena W. Sagoe3, Adjoa Obo-Akwa1, Ernest Kenu2,
Fizza S. Gillani4,5, Hongmei Yang6, Isaac Boamah3, Timothy Flanigan4,5 and Awewura Kwara4,5
Abstract
Background: The global burden of Hepatitis B virus (HBV) and HIV co-infection is enormous. The risk of developing
cirrhosis and hepatocellular cancer is associated with HBV DNA levels. The main objective of the study was to
determine proportion of Hepatitis B viremia in ART-naïve and ART-experienced co-infected Ghanaian patients and
factors associated with HBV viremia after at least 36 weeks of lamivudine with or without tenofovir containing ART.
Methods: Hepatitis B and HIV co-infected patients who were ART-naïve or had received at least 9 months of
lamivudine-containing ART were enrolled in a cross-sectional study at Korle-Bu Teaching Hospital. Demographic
and clinical data were collected and samples obtained for Hepatitis B serology, liver function tests and HBV DNA.
Factors associated with viremia were determined using univariate and multivariate logistic regression analysis.
Results: Of 3108 HIV-infected patients screened, 257 (8.3 %) were HBsAg-positive, of which 235 enrolled. Overall, 152
(64.7 %) were ART-experienced and 83 (35.3 %) were ART-naïve. Eighty-nine-percent of ART-naïve and 42.1 % of
ART-experienced patients had HBV DNA > 20 IU/mL. In multivariate analysis of all patients, being ART-naïve (OR 10.1,
95 % CI 4.6 – 21.9) and elevated ALT (OR 3.7, 95 % CI 1.8 – 7.9) were associated with Hepatitis B viremia. In treatment
experienced patients, elevated ALT (OR 4.8 CI 2.0 – 12.1) and male sex (OR 2.1, 95 % CI 1.0 – 4.2) were associated with
Hepatitis B viremia.
Conclusions: Majority of ART-naïve (89 %) and 42 % of ART-experienced patients had detectable hepatitis B
viremia > 20 IU/mL. An abnormal serum ALT was significantly associated with hepatitis B viremia in HBV and HIV
co-infected patients irrespective of treatment status. Baseline and on-treatment ALT may be a useful non-invasive
predictor of Hepatitis B viremia in resource-constrained countries in sub-Saharan Africa where infection is
endemic and viral load tests are not widely available.
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Background
Globally, it is estimated that there are 240 million per-
sons chronically infected with HBV infection, with a
majority of them living in low- and middle-income coun-
tries [1]. The prevalence of chronic HBV infection varies
from 0.1 – 2 % in industrialized countries to 5 – 10 % in
Sub-Saharan Africa [1]. An estimated 6 to 14 % of HIV-
infected persons worldwide are chronically infected with
HBV [2], with the highest rates occurring in sub-Saharan
Africa and Asia [3]. The natural history of chronic HBV is
negatively affected by HIV co-infection. HBV/HIV co-
infected patients have lower spontaneous HBeAg serocon-
version rates, higher levels of HBV viremia [4], faster
progression to cirrhosis and increased rate of development
of HCC [5].
The risk of developing cirrhosis, hepatic decompensa-
tion and HCC is associated with HBV DNA levels [6, 7].
HIV viremia is also associated with progression of HBV
infection [5]. Thus, suppression of HBV DNA and HIV
RNA to undetectable levels is an important treatment
goal of HIV/HBV-co-infected patients [4, 8, 9]. In treated
HIV/HBV co-infected patients, detectable HBV viremia
has been associated with positive HBeAg, negative anti-
HBe, HBV genotype A, type and duration of ART, CD4
count < 200 cells/mm3, detectable HIV RNA, and <95 %
adherence to ART [10].
In Ghana, the reported prevalence of HBV ranges
from 12 to 15 % among blood donors [11]. At the Fevers
Unit, Korle-Bu Teaching Hospital (KBTH), an earlier
study of 154 HIV patients found the prevalence of HBV
infection was 13 % [12]. In another study in Kumasi,
Ghana, the prevalence of HBV infection in a cohort of
838 HIV-infected patients was found to be 16.7 % [13].
Although HIV patients are increasingly screened for
HbsAg, HBV DNA testing is not routinely done in Ghana
due to cost implications. Until tenofovir became available
in Ghana, the recommendation was to use lamivudine
(3TC)-containing ART for HBV/HIV co-infected persons.
The most recent HIV treatment guidelines recommend
the use of tenofovir (TDF) plus 3TC or emtricitabine in
patients with HBV/HBV co-infection [14]. The HIV
treatment guidelines also recommend using HBV viral
load (where available) and ALT for treatment initiation
and monitoring. The objective of this study was to de-
termine the proportion of HBV viremia in ART-naïve
and treatment-experienced HIV co-infected Ghanaian
patients, and to investigate the factors associated with
viremia after at least 9 months of lamivudine with or
without tenofovir containing ART.
Methods
Study participants and study design
Korle-Bu Teaching Hospital has 2500 beds and is the
main tertiary referral centre in Accra serving the majority
of the southern half of Ghana. The Fevers Unit is the
principal referral centre for infectious diseases in
Southern Ghana with approximately 15,000 HIV pa-
tients under regular follow-up in the out-patient clinic
and over 7000 patients on regular anti-retroviral ther-
apy. It has an in-patient department staffed with doc-
tors, nurses, counselors, para-clinical and laboratory
staff which offers service to a wide range of patients
with infectious diseases including HIV.
This study used a cross-sectional design to recruit HBV-
HIV co-infected patients attending the Fevers (Infectious
Diseases) Unit, Korle-bu, Accra, Ghana between 2012 and
2014. Adult HIV patients attending the Fevers (Infectious
Diseases) Unit during the study period (2012–2014) were
screened for HBsAg using the Core HBsAg rapid test
(Core Diagnostics, Birmingham, UK) following informed
consent. HIV and HBsAg-positive study participants were
enrolled into two groups. The treatment-naive group (t0)
were HBV-HIV co-infected patients who had not initiated
therapy. The treatment-experienced group (t1) were
HBV-HIV co-infected patients who had been on at least
9 months of 3TC containing anti-retroviral therapy. Pa-
tients were excluded if they declined to sign a consent
form for participation. Demographic and clinical data
were collected from enrolled patients using standardized
data collection form. Medical records were also reviewed
where additional clinical and laboratory data including
CD4 cell count extracted as patients did not know their
most recent CD4 count. Adherence status was determined
using the validated Simplified Medication Adherence
Questionnaire (SMAQ) [15]. All extracted data was subse-
quently entered into Microsoft Access.
The Institutional Review Board (IRB) of the University of
Ghana Medical School, Accra, Ghana and Lifespan Hospi-
tals, Providence, Rhode Island reviewed and approved the
study.
Laboratory analysis
Enrolled patients had blood drawn into an EDTA and
serum separating tube (SST). Blood in EDTA was trans-
ported to the Virology Laboratory, Korle-Bu, on ice, cen-
trifuged within 4 h of collection using EBA 20 table-top
centrifuge (Hettich Zentrifugen, Tuttlingen, Germany),
and plasma frozen at −80 in ~ 600 ul aliquots. HBsAg
positivity was confirmed serologically using a third gener-
ation ELISA Surase B 96 (TMB) (General Biologicals
Corp, Hsinchu, Taiwan). Plasma was also tested for Hepa-
titis B e-antigen (HBeAg), Hepatitis B e-antibody (anti-
HBe) using EASE BN-96 (TMB) and Hepatitis B-core
antibody (anti-HBc) using ANTICORASE MB-96 (TMB)
from General Biologicals, Hsinchu, Taiwan. Blood in SST
was tested for liver function. Plasma HBV DNA was deter-
mined using fully automated COBAS® TaqMan® Analyzer
(Roche Diagnostics GmbH, Mannheim, Germany). The
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Table 1 Baseline characteristics of HIV/HBV co-infected patients and by antiretroviral treatment Status
Treatment status
Characteristic All patients (N = 235) Experienced (N = 152) Naïve (N = 83) P value T test P value Wilcoxon
rank sum test
Mean (SD) age (years) 41.0 (10.0) 42.6 (9.5) 37.9 (10.2) 0.0006 <0.0001
Mean (SD) weight (kg) 63.1 (13.4) 64.9 (13.1) 59.6 (13.2) 0.0038 0.0082
Mean (SD) BMI (kg/m2) 23.4 (4.7) 24.2 (4.7) 21.8 (4.5) 0.0001 0.0002
Mean (SD) CD4 count (cells/uL) 460.7 (322) 513 (304) 363 (334) 0.0006 <0.0001
n (%) n (%) n (%) P value Chi square P value Fisher
Sex 0.597 0.677
Female 139 (59.1) 88 (57.9) 51 (61.5)
Male 96 (40.9) 64 (42.1) 32 (38.6)
Ethnicity 0.744 0.762
Akan 109 (46.8) 72 (47.4) 37 (45.7)
Ewe 44 (18.9) 29 (19.1) 15 (18.5)
Ga 28 (12.0) 20 (13.1) 8 (9.9)
Other 52 (22.3) 31 (20.4) 21 (25.9)
WHO HIV stage 0.630 0.619
1 55 (23.7) 38 (25.3) 17 (20.7)
2 58 (25.0) 36 (24.0) 22 (26.8)
3 92 (39.7) 61 (40.7) 31 (37.8)
4 27 (11.6) 15 (10.0) 12 (14.6)
HBeAg positive 47 (20.0) 28 (18.4) 19 (22.9) 0.413 0.495
HBeAb positive 188 (80.0) 122 (80.3) 66 (79.5) 0.891 1.000
HBeAg/eAb combination 0.622 0.604
HBeAg positive/Ab negative 41 (17.5) 25 (16.5) 16 (19.3)
HBeAg negative/Ab positive 182 (77.5) 119 (78.3) 63 (75.9)
HBeAg negative/Ab negative 6 (2.6) 5 (3.3) 1 (1.2)
HBcIgM positive 5 (2.1) 4 (2.6) 1 (1.2) 0.469 0.659
Treatment status
Characteristic All patients Experienced Naïve P value Chi square P value Fisher
N = 235 (%) (N = 152) (N = 83)
n (%) n (%)
Alanine aminotransferase 0.0012 0.0015
Normal (5-40 U/L) 169 (71.9) 120 (79.0) 49 (59.0)
Elevated > ULN 66 (28.1) 32 (21.1) 34 (41.0)
Aspartate aminotransferase 0.0005 0.0008
Normal (5-50 U/L) 178 (75.7) 126 (82.9) 52 (62.7)
Elevated > ULN 57 (24.3) 26 (17.1) 30 (36.1)
Albumin <0.0001 <0.0001
Normal (36-50) 153 (65.1) 117 (77.0) 36 (43.4)
Low < LLN 82 (34.9) 35 (23.0) 47 (56.6)
HBV DNA (IU mL-1) <0.0001 <0.0001
< 20 97 (41.3) 88 (57.9) 9 (10.8)
20 – 2000 58 (24.7) 31 (20.4) 27 (32.5)
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lower limit of detection of the Roche TaqMan assay was
20 IU mL-1 and the linear range 20 – 170,000,000 IU/mL.
Statistical analysis
Statistical analyses were performed using Software SAS
9.3 (SAS Institute Inc, Cary, NC). Bivariate analyses of
association between participant factors and treatment
status or HBV viremia were assessed by Student’s t-test
for continuous variables or Chi-square test for categor-
ical variables. Logistic regression with variable selec-
tion by stepwise was used to find the joint effect of the
participants (treatment status, age, gender, BMI, CD4
counts, serum ALT, AST and ALB) on HBV viremia
using all the data and also using treatment-specific
data, and the findings were confirmed by the Smoothly
Clipped Absolute Deviation (SCAD) method [16, 17].
For all analysis, a P value < 0.05 was considered significant.
Results
Study population and baseline characteristics
During the study period, 3108 HIV-infected patients were
screened for HBV with HBsAg, of which 257 patients
(8.3 %) were HBsAg positive. Two hundred and thirty-five
(235) patients were recruited into the study, with 22
patients either declining consent or had incomplete
data. The baseline characteristics of all patients and by
ART status are shown in Table 1. Overall, 152 (64.7 %)
of the patients were treatment-experienced and 83
(35.3 %) were treatment-naïve. In treatment-naïve and
treatment experienced patients, the median HBV DNA
log10IU/mL was 8.8 (IQR: 4.8–17.6) and 2.9 (IQR: 2.1–
6.8) respectively. The mean (SD) duration of ART in
treatment-experienced patients was 4.2 (2.7) years.
Treatment-experienced and naïve patients were similar
except that treatment-experienced patients were older,
had higher mean weight, higher mean BMI and higher
mean CD4 count Table 1. The ART-experienced patients
were less likely to have serum albumin level below the
lower limit of normal or AST, ALT, and HBV DNA levels
above the upper limit of normal (ULN), Table 1.
Of the 152 treatment-experienced patients, 100
(65.8 %) were on ART with 3TC (3TC), while 52 had re-
ceived 3TC + TDF containing ART, for at least 9 months
prior to sampling (3TC + TDF). Of the (3TC + TDF)
group, 37 (71.2 %) were on combination therapy from
the onset of treatment while 15 (28.8 %) had been on an-
other 3TC containing regimen before changing to 3TC
+ TDF combination therapy.
Table 1 Baseline characteristics of HIV/HBV co-infected patients and by antiretroviral treatment Status (Continued)
2001 - 20, 000 14 (6.0) 4 (2.6) 10 (12.1)
> 20, 000 66 (28.1) 29 (19.1) 37 (44.6)
Initial ART contain
3TC 100 (42.6) 100 (65.8) –
3TC + TDF 52 (22.1) 52 (34.2) –
Duration on ART –
<1 year 4 (1.7) 4 (2.6)
1 – 2 years 38 (16.2) 38 (25.0) –
2 – 3 years 21 (8.9) 21 (13.8) –
> 3 years 89 (37.9) 89 (58.6) –
Ever forgotten meds? 36 (23.7) –
Do you take meds on time? 16 (10.5) –
Stop taking meds due to illness? 12 (7.9) –
Forgotten meds last weekend? 14 (9.2) –
Number of times not taken meds last week?
0 57 (37.5)
1 to 2 10 (6.6)
3 – 5 6 (3.9)
more than 5 3 (2.0)
BMI body mass index
HBeAg/Ab Hepatitis B e Antigen/Antibody
HBcIgM Hepatitis B core IgM
3TC lamivudine
TDF tenofovir
ULN upper limit of normal
LLN lower limit of normal
ART anti-retroviral therapy
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Table 2 Characteristics of antiretroviral treatment-experienced HIV/HBV Co-infected patients with undetectable HBVDNA compared
to those with detectable HBV DNA
Characteristic HBV DNA < 20 HBV DNA≥ 20 P-value T test P-value Wilcoxon rank sum test
IU/mL (N = 64) IU/mL (N = 88)
Mean (SD) age (years) 42.6 (9.6) 42.7 (9.5) 0.928 0.701
Mean (SD) weight (kg) 65.9 (13.7) 63.5 (12.2) 0.262 0.326
Mean (SD) BMI (kg/m2) 24.5 (4.6) 23.9 (4.7) 0.415 0.432
Mean (SD) CD4 count (cells/uL) 539 (257) 478 (358) 0.244 0.157
n (%) n (%) P value Chi square P value Fisher
Male sex 30 (46.9 %) 34 (53.1 %) 0.019 0.021
Ethnicity 0.656 0.679
Akan 43 (59.7 %) 29 (40.3 %)
Ewe 14 (48.3 %) 15 (51.7 %)
Ga 13 (65.0 %) 7 (35.0 %)
Other 18 (58.1 %) 13 (41.9 %)
WHO HIV stage 0.086 0.095
1 24 (63.2 %) 14 (36.8 %)
2 21 (58.3 %) 15 (41.7 %)
3 37 (60.7 %) 24 (39.3 %)
4 4 (26.7 %) 11 (73.3 %)
HBeAg positive 0 28 (100.0 %) <0.0001 <0.0001
HBeAb positive 85 (69.7 %) 37 (30.3 %) <0.0001 <0.0001
HB eAg/E Ab combination <0.0001 <0.0001
HBeAg positive/Ab negative 0 25 (100.0 %)
HBeAg negative/Ab positive 85 (71.4 %) 34 (28.6 %)
HBeAg negative/Ab negative 3 (60.0 %) 2 (40.0 %)
HBeAg positive/Ab positive 0 3 (100.0 %)
HBcIgM positive 0 4 (100.0 %) 0.0175 0.030
Alanine aminotransferase 0.0001 0.0002
Normal (5-40 U/L) 79 (65.8 %) 41 (34.2 %)
Elevated > ULN 9 (28.1 %) 23 (71.9 %)
Aspartate aminotransferase 0.0004 0.0008
Normal (5-50 U/L) 81 (64.3 %) 45 (35.7 %)
Elevated > ULN 7 (26.9 %) 19 (73.1 %)
Characteristic HBV DNA < 20 IU mL-1 HBV DNA≥ 20 IU mL-1 P value Chi square P value Fisher
n (%) n (%)
Albumin 0.096 0.119
Normal (36-50 g/L) 72 (61.5 %) 45 (38.5 %)
Low < LLN 16 (45.7 %) 19 (54.3 %)
Initial ART contain 0.971 1.000
3TC (n = 100) 42 (42.0 %) 58 (58.0 %)
3TC + TDF (n = 52) 22 (42.3 %) 30 (57.7 %)
Duration on ART 0.969 0.972
<1 year 3 (75.0 %) 1 (25.0 %)
1 – 2 years 22 (57.9 %) 16 (42.1 %)
Archampong et al. BMC Infectious Diseases  (2016) 16:14 Page 5 of 9
In the 3TC-only group, the median duration of treat-
ment was 4.85 years (IQR: 3.0–7.1). In the 3TC + TDF
group, median duration of treatment of patients on 3TC
and TDF from the onset was 1.23 years (IQR: 1.1–1.6)
while 4.87 years (IQR: 3.8–5.9) in patients on another
3TC regimen before changing to 3TC + TDF combin-
ation therapy.
Overall, 74 (89.2 %) of the 83 ART-naïve and 64 (42.1 %)
of the 152 ART-experienced patients had HBV DNA>
20 IU/mL (Table 1). Forty-seven (56.6 %) of ART-naïve
and 33 (21.7 %) of ART-experienced patients had HBV
DNA> 2000 IU/mL.
Factors associated with hepatitis B viremia
Bivariate analysis of factors associated with viremia
(HBV DNA > 20 IU/mL) in the treatment-naïve and ex-
perienced patients are shown in Tables 2 and 3. Males
were more likely to have detectable HBV DNA (>20 IU/
mL) in comparison to females during ART (53 % vs
47 %, P = 0.019). An elevated serum AST and ALT above
ULN were also more likely to be associated with detect-
able HBV during ART (P = 0.0004) and (P = 0.0001), re-
spectively. In treated patients, being HBeAg-positive and
HBeAb-negative was significantly associated with detect-
able HBV DNA (P < 0.0001). Treatment regimens (3TC)
and (3TC + TDF) had similar likelihood of hepatitis B
DNA suppression, with undetectable Hepatitis B virus in
42.0 and 42.3 % respectively (P = 0.97). Of the 83
treatment-naïve patients, only 9 (10.8 %) had HBV DNA
< 20 IU/mL.
Factors associated with viremia in multivariate analysis
In multivariate analysis of all patients, naïve patients were
more likely than the treatment-experienced group to have
detectable HBV DNA (OR 10.1, 95 % CI 4.6 – 21.9). Add-
itionally, elevated serum ALT level above ULN compared
with normal ALT was associated with 3.7-fold increase in
likelihood of detectable HBV DNA (OR 3.7, 95 % CI 1.8 –
7.9). Among the treatment-experienced patients, elevated
serum ALT level above ULN compared with normal ALT
(OR 4.8, CI 2.1-12.1) and Male sex compared Female (OR
2.1, 95 % CI 1.0 – 4.2) were more likely to have detectable
HBV DNA (Table 4). Multivariate analysis of treatment-
naïve patients did not yield any significant results due to
small sample size.
Discussion
In this cross-sectional study, we found the prevalence
of detectable HBV DNA ≥ 20 IU/mL in HIV-infected
patients who were HBsAg positive to be 89.1 % in
ART-naïve and 42.1 % in patients on lamivudine con-
taining therapy with or without tenofovir for an aver-
age duration of 4.2 years (range, 9 months to
10.4 years). In all patients, ART status and serum ALT
level above ULN were associated with HBV viremia.
Among the treatment-experienced patients, male sex
and ALT level above ULN were associated with Hepa-
titis B viremia in both univariate and multivariate ana-
lysis. Earlier guidelines recommend that HBV DNA be
fully suppressed by 12 months of TDF-based therapy
in Hepatitis B-HIV infected patients [8, 18]. However,
Table 2 Characteristics of antiretroviral treatment-experienced HIV/HBV Co-infected patients with undetectable HBVDNA compared
to those with detectable HBV DNA (Continued)
2 – 3 years 12 (57.1 %) 9 (42.9 %)
> 3 years 51 (57.3 %) 38 (42.7 %)
Ever forgotten meds? 26 (72.2 %) 10 (27.8 %) 0.046
Do you take meds on time? 8 (50.0 %) 8 (50.0 %) 0.499
Stop taking meds due to illness? 9 (75.0 %) 3 (25.0 %) 0.211
Forgotten meds last weekend? 10 (71.4 %) 4 (28.6 %) 0.282
Number of times not taken meds last week? –
0 35 (61.4 %) 22 (38.6 %)
1 - 2 7 (70.0 %) 3 (30.0 %)
3 – 5 4 (66.7 %) 2 (33.3 %)
more than 5 1 (33.3 %) 2 (66.7 %)
BMI body mass index
HBeAg/Ab Hepatitis B e Antigen/Antibody
HBcIgM Hepatitis B core IgM
3TC lamivudine
TDF tenofovir
ULN upper limit of normal
LLN lower limit of normal
ART anti-retroviral therapy
Archampong et al. BMC Infectious Diseases  (2016) 16:14 Page 6 of 9
incomplete HBV DNA suppression has been shown to
occur in 54 % following 12 months of TDF-based ART [8].
A longer duration of TDF therapy is required for
achievement of virologic response (HBV DNA < 20 IU/
mL) in co-infected patients. Among HBeAg-positive
patients, 92 % (n = 67) had HBV DNA < 20 IU/mL after
5 years of treatment [19]. In HBeAg-negative patients,
100 % (n = 15) achieved undetectable HBV DNA in
4 years [19]. Similarly, after a median of 74.7 months,
86.5 % (n = 111) of co-infected patients demonstrated
a virologic response with HBV DNA < 60 IU/mL [20].
There was no difference between patients with or
without 3TC [19]. Tenofovir-based ART therefore
achieves high HBV DNA suppression ~90 % at 5 years
without evidence of resistance in comparison to 3TC
only ART [21].
In our study, HBV DNA was undetectable in 42.0 and
42.3 % irrespective of whether TDF was included in the
Table 3 Characteristics of antiretroviral treatment-naive HIV/HBV Co-infected patients with undetectable HBVDNA compared to those
with detectable HBV DNA
Characteristic HBV DNA < 20 IU/mL HBV DNA≥ 20 IU/mL P-value T test P-value Wilcoxon rank sum test
(N = 64) (N = 88)
Mean (SD) age (years) 39.6 (8.0) 37.7 (10.4) 0.616 0.288
Mean (SD) weight (kg) 66.2 (9.5) 58.8 (13.4) 0.116 0.092
Mean (SD) BMI (kg/m2) 23.7 (4.9) 21.6 (4.4) 0.184 0.209
Mean (SD) CD4 count (cells/uL) 561.7 (504.5) 338.8 (302.7) 0.228 0.144
n (%) n (%) P-value Chi square P-value Fisher
Male sex 4 (12.5 %) 28 (87.5 %) 0.701 0.728
Ethnicity 0.404 0.381
Akan 6 (16.2 %) 31 (83.8 %)
Ewe 0 (0.0 %) 15 (100.0 %)
Ga 1 (12.5 %) 7 (87.5 %)
Other 2 (9.5 %) 19 (90.5 %)
WHO HIV stage 0.265 0.174
1 & 2 2 (5.1 %) 37 (94.9 %)
3 & 4 7 (16.3 %) 36 (83.7 %)
HBeAg positive 0 (0.0 %) 19 (100.0 %) 0.083 0.110
HBeAb positive 9 (13.6 %) 57 (86.4 %) 0.107 0.193
HBeAg/E Ab combination 0.361 0.339
HBeAg positive/Ab negative 0 (0.0 %) 16 (100.0 %)
HBeAg negative/Ab positive 9 (14.3 %) 54 (85.7 %)
HBeAg negative/Ab negative 0 (0.0 %) 1 (100.0 %)
HBeAg positive/Ab positive 0 (0.0 %) 3 (100.0 %)
HBcIgM positive 0 (0.0 %) 1 (100.0 %) 0.726 1.000
Alanine aminotransferase 0.622 0.731
Normal (5–40 U/L) 6 (12.2 %) 43 (87.8 %)
Elevated > ULN 3 (8.8 %) 31 (91.2 %)
Aspartate aminotransferase 0.320 0.473
Normal (5–50 U/L) 7 (13.5 %) 45 (86.5 %)
Elevated > ULN 2 (6.5 %) 29 (93.6 %)
Albumin 0.945 1.000
Normal (36–50 g/L) 4 (11.1 %) 42 (89.4 %)
Low < LLN 5 (10.6 %) 19 (54.3 %)
BMI body mass index
HBeAg/Ab Hepatitis B e Antigen/Antibody
HBcIgM Hepatitis B core IgM
ULN: upper limit of normal
LLN lower limit of normal
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regimen. The median duration on therapy and IQR for
3TC-only and 3TC + TDF were 4.85 years IQR (3.02–
7.16) and 4.87 years IQR (3.81–5.85) respectively. This
suggests the influence of other factors in sub-optimal
therapeutic response. Poor adherence is often considered
as an important factor in patients with persistently de-
tectable HBV DNA on nucleoside analogue therapy [20].
It is also possible that the 33 (21.7 %), treated patients
with HBV DNA > 2000 IU/mL harbor HBV resistant
mutants. After a median of 45 months of 3TC, HBV
DNA was found to be undetectable (<14 IU/mL) in
49.1 % (n = 106) of co-infected patients in Kumasi,
Ghana [22]. Among patients with detectable HBV DNA,
42.6 % also had detectable HIV RNA [22]. Overall,
29.6 % of patients harbored one or more 3TC resistance
mutations comprising M204I or M24V in all cases [22].
In this study, HIV RNA was not determined. Its
cross-sectional design also did not allow for a temporal
assessment of the influence of study predictors such as
pre-treatment HBV DNA, adherence on virologic re-
sponse in treated patients. Furthermore, the small sample
size of treatment naive patients limited the evaluation of
predictors and detectable HBV DNA.
The serum aminotransferases are sensitive indicators of
liver cell inflammation [23]. The most commonly mea-
sured are ALT and AST. In HBV-infection, high ALT
levels > 30 IU/L in males and 19 IU/L in females, HBV
DNA > 20,000 IU/mL can better differentiate between ac-
tive chronic HBV patients from inactive chronic carriers
[24]. However, an increase in serum ALT in co-infected
patients may be the result of ART hepatotoxicity, drug re-
sistance, immune reconstitution, drug withdrawal, anti-
tuberculous therapy and opportunistic or super-infections
[21, 25]. In our study, an elevated ALT was significantly
associated with viremia in HBV/HIV co-infected patients
irrespective of treatment status. In comparison with
HBeAg status, the relationship between serum ALT and
viremia in treated patients persisted following multivariate
analysis.
We found that males had higher baseline HBV DNA
in comparison to females in naïve and ART-experienced
patients. The reason is unclear, and will be in keeping
with an increased liver-related mortality rate in men
with HIV and HBsAg compared with those with only
HBsAg (14.2/1000 compared with 0.8/1000) [26]. Re-
views in Africa have shown that women are more likely
to access and maintain follow up for HIV care [27, 28].
Additionally, in co-infected patients, women had higher
intracellular trough concentrations of TDF in a pilot
pharmacokinetic study [29]. This raises the possibility of
gender differences in adherence or intracellular concen-
trations of the nucleoside reverse transcriptase inhibitors
diphosphate or triphosphates, which would need evalu-
ation in prospective studies.
Conclusion
Routine Hepatitis B screening is essential in the evalu-
ation and management of HIV patients. Elevated HBV
DNA level is associated with overall mortality in HBV/
HIV co-infected patients, especially during the period
before development of AIDS [30], and it is essential to
identify patients who have viremia for treatment intensifi-
cation. Majority of ART-naïve (89 %) and 42 % of ART-
experienced patients were found to have detectable HBV.
An abnormal serum ALT was significantly associated with
HBV viremia in HBV-HIV co-infected patients irrespective
of treatment status. Baseline and on-treatment ALT may
therefore be a useful non-invasive cost-effective predictor
of HBV viremia in resource-constrained countries in sub-
Saharan Africa where the infection is endemic thereby
assisting in risk stratification of patients for liver-related
complications. Serum ALT may serve as a useful tool on
monitoring disease activity and treatment response in
naïve and ART-experienced patients and could be used
to prioritize when or which patients should get more
costly viral load testing to aid decision about optimizing
treatment.
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